Regeneron Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for their drug Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. This approval is based on the response rate and durability of response observed in the LINKER-MM1 trial. Lynozyfic is poised to potentially become a new standard of care for multiple myeloma due to its 70% overall response rate in heavily pre-treated patients. Regeneron is also advancing a broad clinical development program to explore Lynozyfic's use in earlier lines of therapy and in novel combinations. The company is committed to supporting patients with Lynozyfic Surround™, providing financial and educational resources to aid patients throughout their treatment journey.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.